Skip to Content

Advexin Approval Status

  • FDA approved: No
  • Brand name: Advexin
  • Generic name: p53 tumor suppressor therapy
  • Company: Introgen Therapeutics, Inc.
  • Treatment for: Head and Neck Cancer

Advexin is an investigational targeted molecular therapy for the treatment of head and neck cancer.

In September 2008, Introgen Therapeutics, Inc. announced the receipt Refuse to File Letter from the U.S. Food and Drug Administration (FDA), advising the company that the Biologics License Application (BLA) for Advexin was not sufficiently complete and would not be filed at that time.

Development Status and FDA Approval Process for Advexin

Sep  2, 2008Introgen Receives Notice Advexin U.S. BLA Not Sufficiently Complete to File
Jun 30, 2008Introgen Submits Advexin Regulatory Applications in the U.S. and Europe
Dec 20, 2007Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for Advexin in Advanced Head and Neck Cancer in First Half of 2008

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.